Emily J Erbelding,etc.,al. A Universal Influenza Vaccine: The Strategic Plan for the National Institute of Allergy and Infectious Diseases. The Journal of Infectious Diseases 28 Feb 2018
A priority for the National Institute of Allergy and Infectious Diseases (NIAID) is development of an influenza vaccine providing durable protection against multiple influenza strains, including those that may cause a pandemic, i.e., a universal influenza vaccine. To invigorate research efforts, NIAID developed a strategic plan focused on knowledge gaps in three major research areas, as well as additional resources required to ensure progress towards a universal influenza vaccine. NIAID will use this plan as a foundation for future investments in influenza research and will support and coordinate a consortium of multidisciplinary scientists focused on accelerating progress towards this goal.
See Also:
Latest articles in those days:
- Emergence of a genetically distinct cluster of influenza A(H3N2) viruses within subclade J.2.2 associated with hospitalization during the 2024-2025 season in Auvergne-Rh?ne-Alpes, France 11 hours ago
- Interaction between DEAD-box RNA helicase 10 and influenza PB1 polymerase selectively regulates influenza A virus replication 11 hours ago
- Genetic Diversity of Clade 2.3.4.4b H5Nx High Pathogenicity Avian Influenza Viruses Detected in Korea During the 2025-2026 Winter Season and Pathogenicity of H5N1 and H5N9 Viruses 12 hours ago
- Update and optimization of a multiplex RT-qPCR assay to overcome diagnostic failure in emerging influenza A(H3N2) subclades J.2 and K (Peru, 2024-2026) 12 hours ago
- Antigenic and structural analysis of the influenza hemagglutinin lateral patch 12 hours ago
[Go Top] [Close Window]


